Kriya Medical Technologies bags DCGI license for RT-PCR kit KRIVIDA Novus
New Delhi: Medical devices firm Kriya Medical Technologies has recently received manufacturing licence from the DCGI (Drugs Controller General of India) for its product KRIVIDA Novus, an RT-PCR kit that can detect the Omicron variant and its sub-lineages in 45 minutes. The product has been developed in collaboration with ImmuGenix Bioscience.
Priced at Rs 150 plus taxes, the test is affordable and most suitable for entry point screening at airports, the company said in a statement.
The SARS-CoV-2 Test Kit (Real-time PCR) is an in vitro diagnostic real-time reverse transcription-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs, anterior/mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider.
''Our focus is to make testing for Covid-19 variants faster, affordable and accessible to everyone, thereby enabling swift prevention and timely treatment. Since KRIVIDA Novus can detect the Omicron variant (B.1.1.529) and all its sub-lineages, such as BA.1, BA.2 and BA.3 in 45 minutes, it is most ideal and beneficial for entry point screening at airports and remobilisation of normal conditions in workplace and institutions," Kriya Medical Technologies CEO and Founder Anu Moturi noted.
